Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail.

Recent News:

 

3/24/2015 Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients with Ebola Virus Disease (EVD)
…..Hemispherx’ Next Step in the Fight to Treat Patients with EVD


3/23/2015 Hemispherx Biopharma to Present Data on the Activity of Ampligen® Against the Ebola Virus
….. In Vivo Data at 7th International Symposium on Filoviruses, March 25-March 28, 2015 in Washington, DC


3/20/2015 HEMISPHERX BIOPHARMA ANNOUNCES FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2014 . . . Newly Upgraded Alferon® Facility Completed; Production of New Alferon® API Inventory Commenced in February 2015

3/9/2015 Hemispherx Enters a Collaboration with Emerge Health for the Commercialization of Ampligen for Chronic Fatigue Syndrome (CFS) in Australia and New Zealand …Hemispherx and Emerge Health to Commence Named Patient Sales While Seeking Formal Regulatory Approval

3/2/2015 Hemispherx Biopharma Announces the Completion of the Newly Upgraded Alferon® Facility: Commercial Production of Alferon® is in the Final Stage Integrating Continuous Flow Manufacturing Technology

More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP

 

Investor Relations:

Charles Jones
CJones & Associates Public Relations
888-557-6480
cjones@cjonespr.com